Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lersivirine SCHEMBL508446 | 0.86 | KCNH2 (0.49) | PGRKCNH2CYP3A4PTGDR2 | |
| SCHEMBL5224518 | 0.83 | PGR (0.41) | PGRKCNH2 | |
| Lersivirine SCHEMBL509058 | 0.83 | KCNH2 (0.45) | PGRKCNH2PTGDR2 | |
| SCHEMBL508393 | 0.83 | KCNH2 (0.44) | PGRKCNH2 | |
| SCHEMBL5227947 | 0.82 | PGR (0.40) | PGRKCNH2 | |
| Lersivirine SCHEMBL508803 | 0.82 | KCNH2 (0.44) | PGRKCNH2PTGDR2 | |
| SCHEMBL2717137 | 0.82 | KCNH2 (0.53) | PGRKCNH2CYP3A4PTGDR2 | |
| SCHEMBL2716684 | 0.81 | KCNH2 (0.54) | PGRKCNH2CYP3A4PTGDR2 | |
| SCHEMBL2717095 | 0.81 | KCNH2 (0.42) | PGRKCNH2CYP3A4 | |
| SCHEMBL509057 | 0.81 | PGR (0.41) | PGRKCNH2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | PGR 1045/4885KCNH2 3503/4885CYP3A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.